Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 1, 1996, Pages 69-79

  Gustafsson, D ^a   Elg, M ^a   Lenfors, S ^a   Borjesson I ^a   Teger Nilsson, A C ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Animal models; Anticoagulant agents; Argatroban; Arterial thrombosis; Bleeding time; Heparin; Inogatran; Thrombolysis; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ARGATROBAN; HEPARIN; INOGATRAN; LYSINE ACETYLSALICYLATE; SLONON; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; VEIN THROMBOSIS;

EID: 0029866371     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199601000-00009     Document Type: Article

References (27)

1. Comerota AJ. Operative venous dilatation and its relationship to postoperative deep vein thrombosis. In: Bergqvist D, Comerota AJ, Nicolaides AN, Scurr JH, eds. Prevention of Venous Thromboembolism. Nicosia: Med-Orion Publishing Company, 1994: 31-41.
2. Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 1993; 69: 1-58.
3. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochem 1991; 30: 10363-10370.
4. Mann KG. Prothrombin and thrombin. In: Colman RW, Hirsch J, Marder VJ, Salzman EW, eds. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott, 1994: 184-199.
5. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. Circulation 1994; 89: 1469-1480.
6. Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest 1992; 102: 352S-363S.
7. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23.
8. Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 1991; 9: 247-263.
9. Hladovec J. A sensitive model of venous thrombosis in rats. Thromb Res 1986; 43: 539-544.
10. Freund M, Cazenave JP, Courtney M, Degryse E, Roitsch C, Bernat A, Delebassee D, Defreyn G, Maffrand JP. Inhibitions by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb Haemost 1990; 63: 187-192.
11. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-280.
12. Lenfors S, Marberg L, Wikström S, Jonsson U, Westin-Eriksson A, Gustafsson D. A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyterich tail: thrombolysis experiments with specific thrombin inhibition. Blood Coag Fibrinol 1993; 4: 263-271.
13. Dejana E, Callioni A, Quintana A, de Gaetano G. Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb Res 1979; 15: 191-197.
14. Planes A, Vochelle N. Venous stasis and trauma in hip surgery. In: Bergqvist D, Comerota AJ, Nicolaides AN, Scurr JH, eds. Prevention of Venous Thromboembolism. Nicosia: Med-Orion Publishing Company, 1994: 57-62.
15. Talbot MD, Ambler J, Butler KD, et al. The effects of recombinant desulphatohirudin on arterial thrombosis in rats. Haemost 1991; 21: 73-79.
16. Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994; 113: 1209-1214.
17. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. Circulation 1994; 89: 1449-1468.
18. Weitz JJ, Hudoba M, Hassel D, Marganore J, Hirsch J. Clot-bound thrombin is protected from inhibition of heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
19. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-3623.
20. Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. J Biol Chem 1978; 253: 6908-6916.
21. Holt JC, Niewiarowski S. Biochemistry of alpha granule proteins. Semin Hematol 1985; 22:151-163.
22. Anonymous. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329: 673-682.
23. Teger-Nilsson AC, Gyzander E, Andersson S, et al. In vitro properties of inogatran, a new selective low molecular weight inhibitor of thrombin. Thromb Haemost 1995; 73: 1325.
24. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-884.
25. Cook NS, Kottirsch G, Zerwes HG. Platelet glycoprotein IIb/IIIa antagonists. Drugs of the Future 1994; 19: 135-159.
26. Hirsch DR, Goldhaber SZ. Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy. Chest 1990; 97: 124S-131S.
27. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137-1141.